MLN-977

DB05431ExperimentalSmall molecule

MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

Mechanism: MLN977 is a second generation compound in the class of asthma therapies known as 5-LO inhibitors, which block the production of leukotrienes. Leukotrienes are major mediators of the inflammatory response.
Curator reviewed
Primary indication: Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).Curator reviewed
Formula / weight: C₁₆H₁₉FN₂O₄ · 322.336 g/mol (avg)
Code names: CMI-977 · LDP-977 · MLN-977

Resolves to

Compound

UNIIVNR0T3Q498CAS175212-04-1ChEMBLCHEMBL73148

Structure

InChIKeyYANONWCPCKIWEC-CABCVRRESA-NSMILESNC(=O)N(O)CCC#C[C@@H]1CC[C@@H](COC2=CC=C(F)C=C2)O1

Targets

P09917ALOX5

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MLN-977, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account